Trials / Recruiting
RecruitingNCT06454357
A Clinical Study of B007 in the Treatment of Pemphigus.
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Pemphigus.
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B007 | B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15 |
Timeline
- Start date
- 2024-07-12
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-06-12
- Last updated
- 2024-10-10
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06454357. Inclusion in this directory is not an endorsement.